Mucopolysaccharidosis Ii
📧 Sign up to get email alerts when something new happens for Mucopolysaccharidosis Ii.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-02EMA Authorised: Elaprase (idursulfase) — Takeda Pharmaceuticals International AG Ireland Branch
Elaprase (idursulfase) has been authorised for worldwide or regional use in the EU for mucopolysaccharidosis II (Hunter syndrome).
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT) [Phase 3]
Phase III study update for JR-141 in Mucopolysaccharidosis II (STARLIGHT) shows the trial is active but not recruiting.
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Tividenofusp alfa (DNL310) in pediatric participants with Mucopolysaccharidosis II (Hunter syndrome) c…
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21) [Phase 2]
A Phase 2 study evaluating JR-141 in patients with mucopolysaccharidosis II has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: A Study of JR-141 in Patients With Mucopolysaccharidosis II [Phase 2, Phase 3]
A clinical trial update for JR-141 in Mucopolysaccharidosis II has completed Phase 2 and Phase 3.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II [Phase 1, Phase 2]
An ascending-dose study of the ZFN genome-editing therapy SB-913 in MPS II (Mucopolysaccharidosis II) was terminated; results have been post…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Study of Idursulfase-beta (GC1111) in Hunter Syndrome [Phase 2]
Phase 2 study of Idursulfase-beta (GC1111) for Mucopolysaccharidosis II (Hunter syndrome) is being conducted by Green Cross Corporation. The…
-
CLINICAL_TRIALS trial_result · 2015-05-13Clinical Trial Update: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) [Phase 2, Phase 3]
A phase 2/3 clinical trial of iduronate-2-sulfatase enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome) has completed …
-
CLINICAL_TRIALS trial_result · 2014-11-24Clinical Trial Update: Clinical Trial of Growth Hormone in MPS I, II, and VI [Phase 2, Phase 3]
A clinical trial evaluating growth hormone for Mucopolysaccharidosis I and II (Phase 2/Phase 3) was terminated; results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-03-17Clinical Trial Update: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase [Phase 2, Phase 3]
Extension study update for long-term safety and outcomes in MPS II patients treated with idursulfase (Hunter syndrome).
-
CLINICAL_TRIALS trial_result · 2013-11-07Clinical Trial Update: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy [Phase 4]
Phase 4 trial update on safety and clinical outcomes in young children with Hunter syndrome treated with idursulfase.
-
CLINICAL_TRIALS research · 2013-05-24Clinical Trial Update: Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
Clinical trial update indicating termination of a study designed to detect unrecognized mucopolysaccharidoses in children at rheumatology, h…